Fig. 2

A. Relative cell viability over different concentrations of Olaparib (µM) for DMSO and Olaparib treatments.

B. Relative cell viability over different time points (0h, 24h, 48h, 72h, 96h) for DMSO and Olaparib treatments.

C. Flow cytometry analysis showing cell cycle distribution:
   - subG1: 5.2%, G2/M: 41% for ctr
   - subG1: 3.2%, G2/M: 60% for ATMi
   - subG1: 3.8%, G2/M: 72% for DMSO
   - subG1: 8.7%, G2/M: 30% for ctr
   - subG1: 16%, G2/M: 51% for ATMi
   - subG1: 14%, G2/M: 69% for DMSO

D. BrdU incorporation ratio over different concentrations of Olaparib (µM) for DMSO and Olaparib treatments.

E. Relative colony number over different concentrations of Olaparib (µM) for DMSO and Olaparib treatments.